Battling Blood Disorders: PNH Market Trends and Growth Forecast 2024-2033

The paroxysmal nocturnal hemoglobinuria (pnh) market size has grown rapidly in recent years. It will grow from $3.84 billion in 2023 to $4.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.

The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

Market Overview -
Paroxysmal nocturnal hemoglobinuria (PNH) refers to a rare and acquired hematological disorder characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins on the surface of blood cells. It is a debilitating disorder that leads to premature death and impaired production of blood cells. PNH includes a wide range of symptoms, such as fatigue, shortness of breath, abdominal pain and thrombosis (blood clot formation).

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp

Rising Prevalence Of Blood And Bone Marrow Disorders Fueling The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market
The rising number of blood disorders and bone marrow-related disorders is expected to propel the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market going forward. Blood disorders are medical conditions that affect the composition, function and production of blood and its components. Bone marrow-related disorders occur when either insufficient red, white, or platelet production occurs in the bone marrow or when the blood cells that are generated are damaged or defective. PNH is closely related to blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function and the bone marrow microenvironment. It is a rare blood disorder that is related to bone marrow failure diseases and occurs when a genetic flaw affects how red blood cells and platelets work. For instance, in June 2021, according to the Leukemia Foundation, an Australia-based non-governmental organization, there are more than 110,000 people suffering from blood disorders in Australia. By the year 2035, more than 275,000 Australians are predicted to have blood disorders. Furthermore, in October 2022, according to the Cancer Data in Australia 2021 report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, more than 50 Australians will have a blood cancer diagnosis every day in 2021, up from 47 every day in 2020. Therefore, the rising number of blood disorders and bone marrow-related disorders is driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Competitive Landscape -
Major players in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

Innovative Therapeutic Advancements Lead The Way In Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are focusing on developing new and innovative drugs and therapy to sustain their position in the market. The treatment alternatives and the need for ideal therapy innovation is required in PNH, such as EMPAVELI, a first C3 target therapy. For instance, in May 2021, Apellis Pharmaceuticals Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration's (FDA) approval for EMPAVELI (pegcetacoplan), the first and only targeted C3 therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). Empaveli has the potential to enhance the lives of PNH patients by raising hemoglobin and decreasing the need for blood transfusions. Adults with PNH, including those switching from any C5 inhibitor and patients who have never had medication, could benefit from a new approach to treatment with EMPAVELI. The company has also launched a treatment access and support program, ApellisAssist, which is designed to provide comprehensive product support to EMPAVELI patients throughout their treatment journey. This program provides services and product resources, including insurance support, education and training, as well as financial assistance for eligible patients.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report

Key Segments -
The paroxysmal nocturnal hemoglobinuria (pnh) market covered in this report is segmented -

1) By Treatment Type: Medications; Bone Marrow Transplantation; Blood Transfusion; Immunosuppressive Therapy; Other Treatment Types
2) By Diagnosis Type: Flow Cytometry; High-Resolution Mass Spectrometry; Other Diagnosis Types
3) By End Use: Hospitals; Clinics; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.